This has helped ensure funding bodies such as the National Cancer Institute can focus their resources on prioritised antigens, such as (and of particular relevance to B-ALL) survivin, Wilms’ tumour protein (WT1) and BCR–ABL, to enable the progress of immunotherapy in a directed manner. This evidence concerns the gene BIRC5 and precursor B-cell acute lymphoblastic leukemia.